Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Piramal Enterprises (Voruciclib)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Voruciclib, an oral cyclin-dependent kinases inhibitor. Voruciclib, oral cyclin-dependent kinases (CDK) inhibitor that has been in clinical development for cancer indications and will be developed in combination with other standard of care agents.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 247 Business Park, A – Wing, 6th Floor
  • LBS Marg, Vikhroli (West)
  • Mumbai, Maharashtra 400083
  • India

Piramal Enterprises (Voruciclib) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Piramal Enterprises (Voruciclib)‘s full profile, request access.

Request full access to PitchBook

Piramal Enterprises (Voruciclib) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Piramal Enterprises (Voruciclib)‘s full profile, request access.

Request full access to PitchBook